UHPLC-HRMS data from non-targeted screening for biotransformation products of cytostatic drug imatinib.

ABSTRACT: Imatinib is a selective tyrosine kinase inhibitor used to treat chronic myeloid leukemia. It enters the environment by excretion from the body through urine and feces and is transferred with wastewater to a wastewater treatment plant. There, it can be degraded by activated sludge, forming a number of biotransformation products. Presence of imatinib and its potential transformation products in the environment can impose a high risk to aquatic organisms and human health, therefore it is important to obtain knowledge of its environmental fate. The data presented here is a result of a simulated biodegradation of imatinib at two levels of activated sludge using a batch biotransformation setup, with and without carbon source. The data was acquired with UHPLC-HRMS/MS and processed by MzMine2.36 [

SUBMITTER: Tkalec Z 

PROVIDER: S-EPMC8897666 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature